Variations of beta-cell early-phase insulin secretion in type 2 diabetic patients in different stages.
- Author:
Hui-ju ZHONG
1
;
Min WANG
;
Lan LIAO
;
Hui-ling CHEN
;
Li-juan GUO
Author Information
1. Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Diabetes Mellitus, Type 2;
drug therapy;
metabolism;
Female;
Humans;
Insulin;
metabolism;
Insulin Resistance;
Insulin Secretion;
Insulin-Secreting Cells;
metabolism;
Male;
Middle Aged;
Sulfonylurea Compounds;
therapeutic use;
Time Factors
- From:
Journal of Central South University(Medical Sciences)
2006;31(2):232-235
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the variations of early-phase insulin secretion in Type 2 diabetic patients in different stages.
METHODS:L-arginine stimulative test, fast blood glucose and body mass index (BMI) were evaluated in 40 nomal controls (NC) and 101 Type 2 diabetic patients. The diabetic patients were divided into three groups: newly diagnosed group (n = 35), effectively treated by sulfonylureas group (n = 32) , and secondary failure of sulfonylureas group (n = 34). The indexs of insulin resistance of homeostasis model assessment (HOMA-IR), beta-cell insulin secretion of homeostasis model assessment (HOMA-IS), and the acute insulin response (AIRARG) index were calculated. Some statistical comparisons were done among the 4 groups.
RESULTS:The indexs of HOMA-IR in each group of Type 2 diabetic patients were all higher than those in NC group (P < 0.01). The AIRARG indexs were obviously lower in Type 2 diabetic patients in different stages than those in NC group (P < 0.01), and the subsequence from the highest to the lowest among the groups of diabetic patients was: the newly diagnosed group, the effectively treated by sulfonylureas group, and the secondary failure of sulfonylureas group (P < 0.01). But there was no significant difference in indexs of HOMA-IS between the newly diagnosed group and the effectively treated by sulfonylureas group.
CONCLUSION:There is severe insulin resistance in Type 2 diabetic patients in each stage. The variations of early-phase insulin secretion manifest a vary procedure of obvious deterioration by degrees from the newly diagnosed group to the secondary failure of sulfonylureas group in Type 2 diabetic patients.
